Exports from Ranbaxy plants at Toansa and Dewas to Europe will remain suspended as probes are continuing, European health regulator EMA sai...

Ranbaxy Laboratories said Tuesday it was suspending shipments from two of its plants following US import bans on its products over safety c...

Reacting to the news, shares of the drug maker plunged as much as 2.3 per cent in trade on the BSE, but recouped early morning losses quick...

With almost 40 per cent of generic drugs dispensed in the US coming from India, the USFDA has to look at Indian pharma more closely.

Rejecting sabotage theory at Toansa plant that faces USFDA ban, Ranbaxy denied blaming company's voluntary retirement scheme for problems i...

Investors discounted the net loss of Rs 159 crore as against a net profit of Rs 492 crore in the corresponding quarter last fiscal year.

Shares of Ranbaxy Laboratories moved higher in trade as sentiment turned bullish following strong margins for the quarter ended December.

India’s drug regulator has ordered Ranbaxy to furnish a comprehensive explanation for the violation of manufacturing practices at its Toans...

Days after US FDA banned import of Ranbaxy products to America from its Toansa plant, health regulators of EU & UK have said they are evalu...

Two senior US officials -- Chief of FDA and Head of US EXIM Bank -- will be in India, hoping to give momentum to bilateral dialogues.

Other lapses included usage of un-calibrated and unqualified instruments in laboratory, said the report, which was released two days ago.

The USFDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.

The FDA said the drugmaker is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.

The US Food and Drug Administration's observations regarding the manufacturing practices in the company's plant in Punjab.

The Toansa plant is crucial for the company as about 70 per cent of APIs used in its formulations are said to be manufactured there.

Shares of Ranbaxy Laboratories are near day's low as sentiment turned bearish on reports that two of its plants are under USFDA scanner.

The Toansa plant is crucial for Ranbaxy as about 70% of APIs used in its formulations are said to be manufactured there.